IMP-1 Inhibits Renal Cell Carcinoma 786-O Cell Growth by Targeting EphrinB2 Signaling Pathway. Braz. J. Pharm. Sci. 2023, 59. https://doi.org/10.1590/s2175-97902023e22102 .